<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "https://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="brief-report" dtd-version="1.2" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Immunology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Immunology</journal-title><trans-title-group xml:lang="ru"><trans-title>Russian Journal of Immunology</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-7221</issn><issn publication-format="electronic">2782-7291</issn><publisher><publisher-name xml:lang="en">Russian Society of Immunology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">17465</article-id><article-id pub-id-type="doi">10.46235/1028-7221-17465-EOA</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>SHORT COMMUNICATIONS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Effect of antiseptics on the antibiofilm activity of innate immune peptides</article-title><trans-title-group xml:lang="ru"><trans-title>Влияние антисептиков на антибиопленочную активность пептидов врожденного иммунитета</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Владимирова</surname><given-names>Е. В.</given-names></name><name xml:lang="en"><surname>Vladimirova</surname><given-names>E. V.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Researcher, Laboratory of Design and Synthesis of Biologically Active Peptides, Department of General Pathology and Pathological Physiology</p></bio><bio xml:lang="ru"><p>научный сотрудник лаборатории дизайна и синтеза биологически активных пептидов отдела общей патологии и патологической физиологии </p></bio><email>vladymyrovaliza18@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="ru">ФГБНУ «Институт экспериментальной медицины»</institution></aff><aff><institution xml:lang="en">Institute of Experimental Medicine</institution></aff></aff-alternatives><content-language>ru</content-language><pub-date date-type="pub" publication-format="electronic" iso-8601-date="2026-10-31"><day>31</day><month>10</month><year>2026</year></pub-date><pub-date date-type="collection"><year>2026</year></pub-date><volume>29</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>509</fpage><lpage>514</lpage><history><date date-type="received" iso-8601-date="2026-03-29"><day>29</day><month>03</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-06-20"><day>20</day><month>06</month><year>2026</year></date></history><pub-history><event event-type="received"><event-desc>Received:<date date-type="received" iso-8601-date="2026-03-29"><day>29</day><month>03</month><year>2026</year></date></event-desc></event><event event-type="accepted"><event-desc>Accepted:<date date-type="accepted" iso-8601-date="2026-06-20"><day>20</day><month>06</month><year>2026</year></date></event-desc></event><event event-type="pub"><event-desc>Published:<pub-date date-type="pub" publication-format="electronic" iso-8601-date="2026-10-31"><day>31</day><month>10</month><year>2026</year></pub-date></event-desc></event></pub-history><permissions><copyright-statement xml:lang="en">Copyright ©; , Vladimirova E.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; , Владимирова Е.В.</copyright-statement><copyright-holder xml:lang="en">Vladimirova E.V.</copyright-holder><copyright-holder xml:lang="ru">Владимирова Е.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://rusimmun.ru/jour/article/view/17465">https://rusimmun.ru/jour/article/view/17465</self-uri><abstract xml:lang="en"><p>Bacterial biofilms develop in 65% of nosocomial infections, including wound lesions, where they promote resistance to antibiotics and immune defenses, thus complicating treatment. The ESKAPEE group of bacterial pathogens (<italic>Enterococcus</italic> spp., <italic>Staphylococcus aureus</italic>,<italic> Klebsiella pneumoniae</italic>, <italic>Acinetobacter baumannii</italic>, <italic>Pseudomonas aeruginosa</italic>, <italic>Escherichia coli</italic>, <italic>Enterobacter </italic>spp.) is especially challenging. Antimicrobial peptides of innate immunity are considered as promising agents for the treatment of wound infections caused by such microorganisms, since they possess multiple antibacterial mechanisms, including antibiofilm activity and a lower probability of resistance development. Meanwhile, antiseptic compounds are widely used in management of wound infections as standard tools for the wound surface treatment, thus determining the importance of testing their compatibility with antimicrobial agents to prevent antagonism and maximize the effect of combination therapy. The aim of this study was to evaluate the effect of antiseptics on the antibiofilm activity of synthetic analogs of innate immune peptides. The antiseptics chlorhexidine, prontosan, and betadine, as well as chemically synthesized analogs of innate immune peptides: protegrin-1, micecilin, bactenecin 3.4, and its structural modification (RFR-ChBac3.4(1-14), were used in the study. The numbers of emerging biofilms were determined spectrophotometrically by Crystal Violet staining. It was found that protegrin-1 exhibits antibiofilm activity at the concentration range of 2-4 μM; micecilin, at 4-16 μM; bactenecin 3.4, at 2-8 μM; modified bactenecin 3.4 (RFR-ChBac3.4 (1-14), at 16 μM; chlorhexidine, at 16-32 μg/mL; prontosan, at 4-16 μg/mL, and betadine, at 1562-6248 μg/mL, as tested with <italic>P. aeruginosa</italic> MDR 522/17 and <italic>A. baumannii</italic> 7226/16. It was also shown that the use of peptides in combination with antiseptics may enhance their antibiofilm effects against <italic>P. aeruginosa</italic> and <italic>A. baumannii</italic> biofilms. Synergistic and additive effects against these bacteria were identified for the following combinations: protegrin-1 or micecilin with chlorhexidine, bactenecin 3.4 with chlorhexidine and prontosan, and RFR-ChBac3.4 (1- 14) with chlorhexidine, prontosan, and betadine. Hence, these joint effects represent a promising basis for combined therapy of wound infections.</p></abstract><trans-abstract xml:lang="ru"><p>Бактериальные биопленки вызывают до 65% нозокомиальных инфекций, включая раневые инфекции, где они обеспечивают устойчивость к антибиотикам и иммунной защите, затрудняя лечение. Особую проблему представляют патогены ESKAPEE (<italic>Enterococcus</italic> spp., <italic>Staphylococcus aureus</italic>, <italic>Klebsiella pneumoniae</italic>, <italic>Acinetobacter baumannii</italic>, <italic>Pseudomonas aeruginosa</italic>, <italic>Escherichia coli</italic>, <italic>Enterobacter</italic> spp.). Антимикробные пептиды врожденного иммунитета рассматриваются в качестве перспективных агентов для лечения раневых инфекций, вызванных такими микроорганизмами, так как обладают множественными механизмами антибактериального действия, включая антибиопленочную активность и низкую вероятность развития резистентности. В терапии раневых инфекций широко применяются антисептики как стандартные средства обработки раневой поверхности. Это определяет важность оценки их совместимости с антимикробными пептидами для предотвращения антагонизма и максимизации эффекта комбинированной терапии. Цель исследования – оценка влияния антисептиков на антибиопленочную активность синтетических аналогов пептидов врожденного иммунитета. В работе использовали антисептики хлоргексидин, Пронтосан и бетадин и химически синтезированные аналоги пептидов врожденного иммунитета: протегрин-1, мицецилин, бактенецин 3.4 и его модификацию RFR-ChBac3.4(1-14). Количество образующихся биопленок определяли спектрофотометрически, окрашивая их кристаллическим фиолетовым. Установлено, что протегрин-1 проявляет антибиопленочную активность в диапазоне концентраций 2-4 мкМ, мицецилин – 4-16 мкМ, бактенецин 3.4 – 2-8 мкМ, модификация бактенецина 3.4 – RFR-ChBac3.4(1-14) – 16 мкМ, хлоргексидин – 16-32 мкг/мл, Пронтосан – 4-16 мкг/ мл и бетадин – 1562-6248 мкг/мл в отношении<italic> P. aeruginosa </italic>MDR 522/17 и <italic>A. baumannii</italic> 7226/16. Также показано, что при применении пептидов в комбинации с антисептиками могут усиливаться их антибиопленочные эффекты в отношении биопленок <italic>P. aeruginosa </italic>и <italic>A. baumannii. </italic>Так,<italic> </italic>синергетические и аддитивные эффекты в отношении указанных бактерий выявлены для следующих комбинаций: протегрин-1 или мицецилин с хлоргексидином, бактенецин 3.4 c хлоргексидином и Пронтосаном, RFR-ChBac3.4(1-14) с хлоргексидином, Пронтосаном и бетадином. Таким образом, эти комбинации представляют собой перспективную основу для разработки комбинированной терапии раневых инфекций.</p></trans-abstract><kwd-group xml:lang="en"><kwd>innate immune peptides</kwd><kwd>antiseptics</kwd><kwd>antibiofilm activity</kwd><kwd>wound infections</kwd><kwd>synergism</kwd><kwd>antibiotic resistance</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>пептиды врожденного иммунитета</kwd><kwd>антисептики</kwd><kwd>антибиопленочная активность</kwd><kwd>раневые инфекции</kwd><kwd>синергизм</kwd><kwd>антибиотикорезистентность</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Правительство Российской Федерации</institution></institution-wrap><institution-wrap><institution xml:lang="en">Government of the Russian Federation</institution></institution-wrap></funding-source><award-id>FGWG 2025-0005</award-id></award-group><funding-statement xml:lang="ru">Исследование выполнено в рамках государственного задания ФГБНУ «Институт экспериментальной медицины» № FGWG 2025-0005.</funding-statement><funding-statement xml:lang="en">The study was carried out within the framework of the state assignment of the Federal State Budgetary Scientific Institution “Institute of Experimental Medicine” No. FGWG 2025-0005.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev., 2006, Vol. 58, no. 3, pp. 621-681.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Chung P.Y., Khanum R. Antimicrobial peptides as potential anti-biofilm agents against multidrug-resistant bacteria. J. Microbiol. Immunol. Infect., 2017, Vol. 50, no. 4, pp. 405-410.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>de Souza G.S., de Jesus Sonego L., Santos Mundim A.C., de Miranda Moraes J., Sales-Campos H., Lorenzón E.N. Antimicrobial-wound healing peptides: Dual-function molecules for the treatment of skin injuries. Peptides, 2022, Vol. 148, 170707. doi: 10.1016/j.peptides.2021.170707.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Fernández L., Breidenstein E.B., Hancock R.E. Creeping baselines and adaptive resistance to antibiotics. Drug Resist. Updat., 2011, Vol. 14, no. 1, pp. 1-21.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Hancock R.E.W., Alford M.A., Haney E.F. Antibiofilm activity of host defence peptides: complexity provides opportunities. Nat. Rev. Microbiol., 2021, Vol. 19, no. 12, pp. 786-797.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Mangoni M.L., McDermott A.M., Zasloff M. Antimicrobial peptides and wound healing: biological and therapeutic considerations. Exp. Dermatol., 2016, Vol. 25, no. 3, pp. 167-173.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Merritt J.H., Kadouri D.E., O’Toole G.A. Growing and analyzing static biofilms. Curr. Protoc. Microbiol., 2005, Chapter 1, Unit 1B.1. doi: 10.1002/9780471729259.mc01b01s00.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Mwangi J., Hao X., Lai R., Zhang Z.Y. Antimicrobial peptides: new hope in the war against multidrug resistance. Zool. Res., 2019, Vol. 40, no. 6, pp. 488-505.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Zurawski D.V., Serio A.W., Black C., Pybus B., Akers K.S., Deck D.H., Johnson S., Chattagul S., Noble S.M., Raynor M., Lanteri C.A. A Review of omadacycline for potential utility in the military health system for the treatment of wound infections. Mil. Med., 2024, Vol. 189, no. 5-6, pp. e1353-e1361.</mixed-citation></ref></ref-list></back></article>
